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Abstract
Background: Hepatic metastases of carcinoid tumors cause incapacitating symptoms, but are
usually diffuse and therefore unresectable. In this article we evaluate our experiences with local
treatment techniques in the management of carcinoid patients with hepatic metastases and failing
systemic treatment.
Methods: Fifteen consecutive carcinoid patients (11 men and 4 women; median age 60 years;
range 45–71 years) were treated with either hepatic artery embolization (HAE) with Ivalon
particles or radiofrequency ablation (RFA) (percutaneously or intra-operatively). Follow-up
evaluation was performed by CT scan and 24-hours urinary 5-HIAA excretions.
Results: A total of 18 HAE's was performed in 13 patients, while 10 lesions in 3 patients were
treated with RFA. Median follow-up was 12.5 months (2 – 25 months). Median duration of
symptoms was 22 months (8 – 193 months). Median overall decrease of 5-HIAA excretion 2
months after HAE was 32% with tumor regression on CT-scan in 4 patients (30%) and
improvement of symptoms with a median duration of 15 months in 3 of them (23%). Embolization
led to fatal hepatic failure in one patient. The 3 patients treated with RFA showed a decrease of
urinary 5-HIAA values of 34, 81 and 93% respectively, with tumor regression in all of them.
Improvement of symptoms was reported in 2 patients up to 25 months.
Conclusion:  Liver embolization performed late in the clinical course had limited effect on
symptoms and biochemical and radiological parameters. First experiences with RFA are favorable
and might encourage to apply RFA more widely in metastatic carcinoid.
Background
Carcinoid tumors are derived from neuroendocrine cells
and are usually slowly growing malignant tumors with
distinct morphological characteristics. Most frequently,
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carcinoids are located in the appendix and ileum, but they
are also known to arise from other sites, such as the bron-
chus and pancreas. The carcinoid syndrome is mostly due
to hepatic metastases with the release of hormones, such
as serotonin, directly into the systemic circulation and is
characterized by symptoms of flushing, diarrhea, and
wheezing. Eventually right-sided heart-valve fibrosis may
develop.
There are several treatment options in metastatic disease.
A multidisciplinary approach is advocated, in which gas-
troenterologists, medical oncologists and surgeons all
have a role [1]. Systemic treatment is aiming at sympto-
matic improvement and reduction of hormonal secretion.
Somatostatin analogues, interferon-alpha and application
of meta-iodobenzylguanidin (MIBG), pharmacological or
combined with radioactive MIBG, can result in long-last-
ing palliation [2-6]. However, tumor reduction is only
occasionally described with these treatment modalities
and as tumor load increases, symptomatic treatment grad-
ually fails.
Local treatment of hepatic metastases of carcinoid is
attractive because of the slow and localized growth pat-
tern. When metastases are restricted to one lobe of the
liver a hemihepatectomy or segmental resection is advo-
cated. Unfortunately, the metastases are often multiple
and diffuse and therefore resection is usually impossible
due to anatomical location or number or due to inade-
quate viable liver tissue that would remain after surgery. If
feasible, hepatic resection can be performed safely and
provides effective palliation with considerable duration
[7].
Another local treatment option is hepatic artery emboliza-
tion (HAE), which not only may ameliorate symptoms
but also might reduce tumor burden. An objective bio-
chemical response of up to 52% and a median duration of
effect of 12 months have been reported in cases of failing
systemic therapy [8]. Reports on chemoembolization
show a slightly better biochemical response and tumor
response [9].
Although radio frequency ablation (RFA) is a fairly new
technique, various studies have demonstrated its effective-
ness in the treatment of unresectable hepatocellular carci-
nomas and hepatic metastases of colon carcinoma
[10,11]. In patients with diffuse hepatic metastasis RFA
could achieve local tumor control while remaining
enough functional liver tissue. Previous reports on RFA of
hepatic carcinoid metastases are limited to case reports
and small series but have indicated good local tumor con-
trol and acceptable morbidity [8,12-15].
Besides our experience in HAE, we have recently intro-
duced the use of RFA in carcinoid patients. In this article
we describe our experience of local treatment techniques
in our institutional series of unresectable hepatic metas-
tases of carcinoids and failing systemic therapy.
Patients and methods
Patients
Among 46 patients with carcinoid syndrome treated in
the Netherlands Cancer Institute/ Antoni van Leeuwen-
hoek Hospital between January 2000 and June 2002 we
evaluated the data of all patients (n = 15) who were
treated with either hepatic artery embolization or RFA.
Table 1: Characteristics of patients





Gender Primary tumour Local therapy Location of 
therapy
1 45 78 F unknown emb. right
2 67 24 M unknown emb. right
3 53 11 M rectum emb. bilat.
4 71 67 M lung emb. right
5 70 63 F lung emb. right
6 60 26 M ileocoecal emb. bilat.
7 62 24 M appendix emb. left
8 60 11 F ileocoecal emb. right
9 61 23 M lung emb. right
10 71 10 M unknown emb. bilat.
11 52 21 M ileocoecal emb. bilat.
12 59 16 M unknown emb. bilat.
13a 55 11 M ileocoecal emb. right
13b 55 17 M ileocoecal RFA left
14 47 8 F ileocoecal RFA bilat.
15 60 193 M ileum RFA bilat.World Journal of Surgical Oncology 2005, 3:75 http://www.wjso.com/content/3/1/75
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Indications were progressive disease with systemic treat-
ment and multiple hepatic metastases not amenable for
resection, because of diffuse localization and bilobar
involvement. Somatostatine analogues, interpheron-
alpha and meta-iodobenzylguanidin, pharmacological or
combined with radioactive MIBG could no longer amelio-
rate symptoms in these patients. Treatment with RFA was
selected in patients where this was technically possible
and all metastases could be treated with sufficient remain-
ing functional liver tissue and with safe margins to the
portal vein. Before treatment CT scans were performed
and urinary 5-hydroxyindole acetic acid (5-HIAA) excre-
tion was measured.
Embolization
The radiographic procedure was started with a diagnostic
arteriography of the celiac axis and the superior
mesenteric artery using the Seldinger technique to assess
arterial anatomy. The portal vein patency was assessed on
pre-embolization CT scan. Thereafter selective catheterisa-
tion was performed of the arterial supply of the right (seg-
ment 5–8) or left (segment 2–4) lobe pending on
localization of the largest metastatic area. Ivalon particles
150–600 µ in polyvinyl alcohol mixed with an iodined
contrast medium were injected until stasis was obtained.
When tumor was present in both lobes of the liver, both
lobes were embolized with an interval of several months
starting with the lobe with the largest tumor load. In these
cases, evaluation of symptoms and biochemical and radi-
ological signs was assessed after the second embolization.
After treatment vital signs, as well as hepatic and renal
functions were monitored on the ward regularly. An ade-
quate diuresis was ensured by careful hydration to avoid
hepatorenal failure in the post-embolization period
Radiofrequency ablation
RFA was performed either intraoperatively or percutane-
ously. A 3.5 or 3.0 LeVeen Needle was used in combina-
tion with a 90 watts radio wave generator
(Radiotherapeutics, USA). After ultrasound-guided inser-
tion of the needle, sequential increase per minute of the
radio wave current was performed until a maximum of 90
watts was achieved. An increase in resistance ultimately
resulted in a "roll off", after which a second procedure at
the same localization was restarted after a one-minute
interval without current, to a maximum of 70% of the first
achieved level. Each localization was thus treated, or a
combination of multiple passes of the LeVeen needle was
used to cover a metastasis larger than 4 cm until complete
tumor necrosis was achieved.
During follow-up symptoms and measurement of urinary
5-HIAA's were evaluated at least every 3 months in our
outpatient clinic. Tumor size and necrosis of tumor were
evaluated by a CT scan at 3, 6 and 12 months after treat-
ment. In the patients who were treated with RFA an addi-
tional CT scan one month after the procedure was
performed.















1 1736 unknown unknown unknown = 2(†) no
2 35 23 23 progression ↓ 4(†) postembolization 
syndrome
3 120 160 42 progression = 7(†) hepatic failure
4 1924 1549 1432 progression = 10(†) no
5 111 75 123 progression 
(after 9 months)
= 11(†) postembolization 
syndrome
6 1662 1564 2022 progression = 12(†) no
7 1740 1617 1604 progression 
(after 5 m)
=1 4 a b s c e s s
8 913 140 566 regression ↑ 14 postembolization 
syndrome
9 1961 1531 2050 no change = 14(†) postembolization 
syndrome
10 72 33 118 regression ↑ 15 no
11 875 720 765 progression = 15 no
12 1529 165 502 regression ↑↑ 22 postembolization 
syndrome
13a 2618 1458 1186 regression = 6* no
13b 1186 777 1815 regression = 7 no
14 91 6 32 regression ↑ 13 cholestasis
15 277 52 79 regression ↑ 25 no
(↓: worsening of symptoms, =: no change, ↑: improvement of symptoms, ↑↑: free of symptoms).World Journal of Surgical Oncology 2005, 3:75 http://www.wjso.com/content/3/1/75
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Results
Eighteen hepatic artery embolizations were performed in
13 patients and 10 metastases were treated with RFA in 3
patients (table 1). There were 11 men and 4 women with
a median age of 60 years (range 45 to 71) at time of treat-
ment. The primary tumor was located in the ileocoecal
area in 7 patients, rectum in 1 patient, lung in 3 patients,
while in the remaining 4 patients the primary tumor was
unknown.
Indications for RFA were a vascular anomaly because of
which HAE could not be performed in 1 patient. The other
patients treated with RFA had very large lesions among
several smaller ones, which made them more appropriate
for RFA. The diagnosis of metastatic disease was known
during a considerable time before local treatment
(median duration of symptoms: 22 months, range: 8–193
months). As shown in table 2, 14 of the 15 patients had
elevated urinary 5-HIAA excretion values with a median of
913 µmol/24 hrs (range 35 – 2618 µmol/24 hrs) (normal
<40 µmol/24 hrs) prior to embolization. Median follow-
up from completion of therapy was 12,5 months (range 6
– 25 months). Seven patients were dead at the time of
analysis.
Embolization resulted in an overall median decrease of 5-
HIAA excretion of 32% (range 0–89%) at first follow-up.
In 3 patients, (23%; 95%-confidence interval: 5–54%) the
decrease after embolization was more than 50% and met
the criteria of biochemical response (patient 8, 10 and
12). In these 3 patients, symptoms improved, including
patient 12 who were free of symptoms after bilateral
embolization. This symptomatic improvement in the
patients with biochemical response was still present at fol-
low-up of 14, 15 and 22 months respectively. In the
remaining ten patients only a minimal biochemical
response was achieved with no effect on symptoms.
Tumor regression on CT scan was present in 4 patients,
which corresponded with symptomatic improvement in
three of them. In 7 patients CT-scans revealed progression
and in one there was no change in tumor size. In one
patient radiological evaluation could not be performed as
this patient died after two months because of cardiac fail-
ure.
Postembolization syndrome, characterized by elevated
levels of transaminases, lactate dehydrogenase and alka-
line phosphatase combined with fever, occurred in 5
patients. All recovered within 10 days. More serious com-
plications occurred in 2 cases. In one patient (nr.7) a
necrotic tumor metastasis was infected, for which treat-
ment with intravenous antibiotics and abscess drainage
was needed. After embolization of the left artery in
another patient (nr.3), embolization of the right hepatic
artery was performed after 5 months, which led to fatal
hepatic failure 2 months later. Six other patients died dur-
ing follow-up because of non-intervention related prob-
In patient 12 the initial CT-scan (figure 1A) of the liver shows multiple small nodules in both liver lobes Figure 1
In patient 12 the initial CT-scan (figure 1A) of the liver shows multiple small nodules in both liver lobes. After HAE (figure 1B) 
the metastases are confluent and the total volume of the liver has decreased remarkably. Symptoms improved and a biochemi-
cal response was obvious.World Journal of Surgical Oncology 2005, 3:75 http://www.wjso.com/content/3/1/75
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lems after 2 to 14 months: right sided cardiac failure (n =
2), progressive disease (n = 2), carcinoid crisis with renal
failure (n = 1) and pneumonia (n = 1).
Treatment with RFA induced a biochemical response in 2
out of 3 patients with a 5-HIAA reduction of 81% and
93%. They also experienced a radiological response, and a
symptomatic improvement. Patient 14 underwent RFA for
one large and several smaller lesions. Patient 15 under-
went a resection of segment 6 and 7, because of a large
lesion of 7 cm in diameter and RFA of 5 other lesions. In
the patient with the longest follow-up the decrease in 5-
HIAA excretion after 26 months was still 71% and symp-
toms were minimal without additional systemic treat-
ment.
In patient 13 with a favorable response to embolization of
the right hepatic artery, embolization of the left hepatic
artery was technically impossible because of a vascular
anomaly. He was subsequently treated with multiple
passes of RFA percutaneously for two large lesions (6 and
7 cm in diameter) in the let lobe under spinal anesthesia
leading to a further reduction in 5-HIAA excretion. How-
ever, although CT scans after RFA showed no recurrence of
tumor, duration of decreased 5-HIAA values lasted only 3
months and a relief of symptoms could not be obtained.
No serious adverse effects occurred after RFA. In one
patient (nr.14) post-operative cholestasis was present. A
magnetic resonance cholangiopancreatography revealed a
minor stenosis of the common bile duct. Symptoms com-
pletely recovered after 2 months and hepatic values
returned to normal values after 3 months, without addi-
tional treatment.
Discussion
In carcinoid tumors with liver metastases patients suffer
from the production of vasoactive hormones. Various sys-
temic treatments are available to diminish the incapacitat-
ing symptoms of the carcinoid syndrome. Somatostatin
analogues are widely applied and reduce these symptoms
in approximately 70%, while a biochemical response is
achieved in 42% up to 72% and a duration of up to a year
[2,6]. Interferon-alpha has demonstrated similar effects
[3]. Application of meta-iodobenzylguanidin (MIBG), in
a pharmacological dosage or combined with radioactive
MIBG, can give long-lasting palliation [4,5]. Local treat-
ment of the liver, however, remains favorable due to
reduction of the tumor load. The metastases are usually
not amenable for resection, but HAE and the newer tech-
nique of RFA might be effective in the treatment of these
patients.
Results of local treatment of this tumor are specifically
interesting because of its histological characteristics. Arte-
rial hypervasculation of liver metastases from carcinoid
tumors argues in favor of hepatic arterial embolization. In
addition, it is thought that RFA might have a specific effect
This slide of the CT-scan of patient 14 shows one dominant metastasis in the right liver lobe, but several other small nodules  are present (figure 2A) Figure 2
This slide of the CT-scan of patient 14 shows one dominant metastasis in the right liver lobe, but several other small nodules 
are present (figure 2A). After RFA necrosis with typical cystic appearance developed (figure 2B).World Journal of Surgical Oncology 2005, 3:75 http://www.wjso.com/content/3/1/75
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on carcinoid tumors, because of the increased conduction
of frictional heating in the hypervascular tissue, resulting
in more extensive coagulative necrosis.
Results of HAE and chemoembolization in earlier reports
are variable [8,16-19]. Symptomatic improvement after
HAE is reported to occur in 64% to 90% [17-19]. Reports
on chemoembolization show a slightly better biochemi-
cal and tumor response [9,16]. In our series, however, a
symptomatic improvement and a corresponding objective
biochemical response are only seen in 3 of 13 (23%)
patients treated with HAE. The median decrease of urinary
5-HIAA excretion was 32%. It can be hypothesized that
HAE was applied to late in the clinical course. The optimal
moment of embolization in the clinical course has been
discussed in a Swedish study of 29 patients with carcinoid
syndrome, but early embolization appeared to be as effec-
tive as late embolization [8]. In addition, side effects in
our series were impressive leading to a protracted recovery
in several cases. It must be noted that all patients had a
considerable duration of symptoms before treatment
(median 22; range 8 – 193) and systemic therapy was fail-
CT-scan of patient 13 reveals several small and larger metastases in both liver lobes (figure 3A) Figure 3
CT-scan of patient 13 reveals several small and larger metastases in both liver lobes (figure 3A). HAE of the right liver lobe 
resulted in fair tumor reduction (figure 3B). Two large metastases in the left liver lober were treated by RFA and show charac-
teristic cystic appearance (figure 3C). The end result six months after the RFA treatment shows a significant decrease of tumor 
mass in both liver lobes (figure 3D).World Journal of Surgical Oncology 2005, 3:75 http://www.wjso.com/content/3/1/75
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ing. Remarkably, the 3 patients that did benefit from this
treatment had a relatively short duration of symptoms
(10, 11 and 16 months). This suggests that embolization
in an earlier stage might be more effective.
The question is if the same holds true for RFA. RFA might
offer a more simple local treatment compared to HAE. The
good local tumor control with a satisfactory duration of
effect on symptoms has been suggested in several reports
of carcinoid patients [12-15]. Although the experience is
limited to small series, this may indicate that an early
intervention with RFA is favorable.
In our report the three patients treated with RFA showed
an impressive biochemical response. RFA could amelio-
rate symptoms in 2 of three patients with duration of over
13 and 25 respectively. Although the measured 5-HIAA
values before treatment in these 2 patients were relatively
low, they suffered from incapacitating symptoms at this
point and a considerable decrease in 5-HIAA values as
well as improvement of symptoms could be reached after
RFA. Complications are reported to be minimal and
include hepatic failure, hepatic abscess and hepatic infarc-
tion [10,12]. In our report one case of transient cholestasis
occurred after RFA. In our series RFA is a safe and, when
performed percutaneously, a minimally invasive proce-
dure which may provide good local tumor control.
Although these results are only first experiences, the excel-
lent biochemical response and duration of symptomatic
improvement encourage considering this technique as a
treatment in cases of metastatic carcinoid syndrome.
Difficulty in evaluating local ablation methods lies in the
fact that patients with advanced stage carcinoid syndrome
all have specific characteristics, e.g. duration and degree of
symptoms, localization of hepatic metastases and site of
the primary tumor. To further explore the possibilities and
indications of local treatment options all these factors
should be taken account for in future studies.
Conclusion
We find these results encouraging to broaden the indica-
tion of treatment with RFA and to reconsider the time of
treatment with embolization. The treatment of carcinoid
syndrome remains a challenge for the physician and all
therapeutic options must be considered carefully.
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